Author of the publication

Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial

, , , , , , , , , , , , , , , , , , , , , and . Lancet Healthy Longev., 3 (6): e417--e427 (June 2022)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

No persons found for author name Kather, Jakob N
add a person with the name Kather, Jakob N
 

Other publications of authors with the same name

Explainable artificial intelligence in skin cancer recognition: A systematic review, , , , , , , , , and 23 other author(s). Eur. J. Cancer, (May 2022)Deep learning can predict survival directly from histology in clear cell renal cell carcinoma, , , , , , , , , and 7 other author(s). PLoS One, 17 (8): e0272656 (August 2022)Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions, , , , , , , , , and 11 other author(s). Gut, (May 2022)Artificial intelligence-based detection of FGFR3 mutational status directly from routine histology in bladder cancer: A possible preselection for molecular testing?, , , , , , , , , and 1 other author(s). Eur. Urol. Focus, 8 (2): 472--479 (March 2022)Integration of deep learning-based image analysis and genomic data in cancer pathology: A systematic review, , , , , , , , and . Eur. J. Cancer, (January 2022)Deep learning-based classification of kidney transplant pathology: a retrospective, multicentre, proof-of-concept study, , , , , , , , , and 13 other author(s). Lancet Digit. Health, 4 (1): e18--e26 (January 2022)Model soups improve performance of dermoscopic skin cancer classifiers, , , , , , , , , and 23 other author(s). Eur. J. Cancer, (September 2022)Response to letter entitled: Re: Integration of deep learning-based image analysis and genomic data in cancer pathology: A systematic review, , , , , , , , and . Eur. J. Cancer, (September 2022)Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial, , , , , , , , , and 12 other author(s). Lancet Healthy Longev., 3 (6): e417--e427 (June 2022)Diagnostic performance of artificial intelligence for histologic melanoma recognition compared to 18 international expert pathologists, , , , , , , , , and 18 other author(s). J. Am. Acad. Dermatol., 86 (3): 640--642 (March 2022)